PT - JOURNAL ARTICLE AU - Junko S. Takeuchi AU - Ami Fukunaga AU - Shohei Yamamoto AU - Akihito Tanaka AU - Kouki Matsuda AU - Moto Kimura AU - Azusa Kamikawa AU - Yumiko Kito AU - Kenji Maeda AU - Gohzoh Ueda AU - Tetsuya Mizoue AU - Mugen Ujiie AU - Hiroaki Mitsuya AU - Norio Ohmagari AU - Wataru Sugiura TI - SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2 AID - 10.1101/2021.11.06.21265632 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.06.21265632 4099 - http://medrxiv.org/content/early/2021/11/08/2021.11.06.21265632.short 4100 - http://medrxiv.org/content/early/2021/11/08/2021.11.06.21265632.full AB - Background The humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon coronavirus disease 2019 (COVID-19) vaccination remain to be clarified. Hence, we aimed to investigate the chronological changes in SARS-CoV-2 specific IgG antibody, neutralizing antibody, and T cell responses during and after receiving the BNT162b2 vaccine.Methods We performed serological, neutralization, and T cell assays among 100 hospital workers aged 22-73 years who received the vaccine. We conducted five surveys on day 1, day 15, day 29 (seven days after the second dose), day 61, and days 82–96 following the first dose.Results SARS-CoV-2 spike protein-specific IgG (IgG-S) titers and T cell responses increased significantly following the first vaccination dose. The highest titers were observed on day 29 and decreased gradually until the end of the follow-up period. There was no correlation between IgG-S and T cell responses. Notably, T cell responses were detected on day 15, earlier than the onset of neutralizing activity.Conclusions This study demonstrated that both IgG-S and T cell responses were detected before acquiring sufficient levels of SARS-CoV-2 neutralizing antibodies. These early immune responses are sustained for approximately six–ten weeks following the second vaccination dose.Competing Interest StatementThe authors (except Gohzoh Ueda) declare no conflict of interest. Gohzoh Ueda is one of employees of Abbott Japan, which provided the antibody assay reagents and funding for the present study.Funding StatementThis work was funded by Abbott Japan (grant number 20C050), the NCGM COVID-19 Gift Fund (grant number 19K059), the Japan Health Research Promotion Bureau Research Fund (grant number 2020-B-09), and a grant from the National Center for Global Health and Medicine (grant number 21A006).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethics Committee of NCGM, Japan (approval number: NCGM-A-004175-00).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is not publicly available due to ethical restrictions and participant confidentiality concerns, but de-identified data is available upon reasonable request to the authors.